Dafydd G Thomas Selected Research

Transcription Factors (Transcription Factor)

1/2015	CIC-DUX sarcomas demonstrate frequent MYC amplification and ETS-family transcription factor expression.
11/2013	Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis.
9/2013	Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma.
3/2012	Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma.
4/2010	Curcumin promotes apoptosis, increases chemosensitivity, and inhibits nuclear factor kappaB in esophageal adenocarcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dafydd G Thomas Research Topics

Disease

78	Neoplasms (Cancer) 01/2023 - 07/2002
17	Adenocarcinoma of Lung 01/2017 - 07/2002
16	Adenocarcinoma 09/2015 - 11/2003
15	Sarcoma (Soft Tissue Sarcoma) 01/2018 - 03/2002
13	Breast Neoplasms (Breast Cancer) 01/2021 - 03/2002
13	Lung Neoplasms (Lung Cancer) 01/2018 - 12/2002
11	Neoplasm Metastasis (Metastasis) 01/2018 - 07/2003
8	Osteosarcoma (Osteogenic Sarcoma) 01/2019 - 07/2003
8	Carcinoma (Carcinomatosis) 11/2014 - 04/2006
6	Ewing Sarcoma (Sarcoma, Ewing) 01/2019 - 05/2006
6	Carcinogenesis 06/2015 - 02/2003
5	Synovial Sarcoma (Synovioma) 01/2018 - 02/2005
5	Metaplasia 08/2016 - 01/2004
4	Circulating Neoplastic Cells 01/2021 - 06/2015
4	Hyperplasia 07/2014 - 02/2003
4	Hemangiosarcoma (Angiosarcoma) 09/2013 - 07/2009
3	Melanoma (Melanoma, Malignant) 12/2022 - 09/2004
3	Necrosis 01/2015 - 07/2003
3	Barrett Esophagus (Barrett's Esophagus) 06/2014 - 06/2007
3	Adrenocortical Adenoma (Disease, Conn's) 09/2012 - 02/2003
3	Adrenocortical Carcinoma 09/2012 - 02/2003
2	Pancreatic Neoplasms (Pancreatic Cancer) 07/2020 - 06/2015
2	Leiomyosarcoma 01/2018 - 07/2009
2	Ductal Carcinoma 10/2017 - 11/2014
2	Lymphoma (Lymphomas) 01/2017 - 06/2013
2	Ovarian Neoplasms (Ovarian Cancer) 12/2015 - 03/2008
2	Retinoblastoma (Glioblastoma, Retinal) 11/2015 - 08/2012
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2014 - 12/2013
2	Adenoma (Adenomas) 09/2012 - 11/2009
2	Infections 06/2012 - 01/2003
2	Follicular Adenocarcinoma 11/2009 - 04/2006
2	Neurofibrosarcoma (MPNST) 07/2009 - 05/2006
1	Squamous Cell Carcinoma of Head and Neck 12/2022
1	Colorectal Neoplasms (Colorectal Cancer) 02/2019
1	Rectal Neoplasms (Rectal Cancer) 02/2019

Drug/Important Bio-Agent (IBA)

35	Proteins (Proteins, Gene)FDA Link 10/2020 - 07/2002
15	Biomarkers (Surrogate Marker)IBA 12/2022 - 07/2002
15	Messenger RNA (mRNA)IBA 01/2018 - 03/2002
10	OligonucleotidesIBA 04/2010 - 12/2002
8	Protein Isoforms (Isoforms)IBA 09/2015 - 07/2002
7	DNA (Deoxyribonucleic Acid)IBA 12/2013 - 02/2003
6	EnzymesIBA 07/2020 - 07/2002
5	RNA (Ribonucleic Acid)IBA 01/2018 - 03/2002
5	Estrogen ReceptorsIBA 01/2017 - 03/2013
5	Transcription Factors (Transcription Factor)IBA 01/2015 - 04/2010
4	AntigensIBA 01/2023 - 09/2004
4	AntibodiesIBA 01/2018 - 05/2006
4	CateninsIBA 01/2018 - 03/2008
4	polyacrylamideIBA 03/2004 - 09/2002
3	Monoclonal AntibodiesIBA 01/2021 - 03/2002
3	Keratins (Keratin)IBA 01/2019 - 09/2002
3	Imatinib Mesylate (Gleevec)FDA Link 01/2018 - 07/2009
3	Peptides (Polypeptides)IBA 10/2017 - 04/2007
3	Cytochrome P-450 CYP3AIBA 10/2017 - 07/2003
3	Insulin-Like PeptidesIBA 09/2014 - 02/2003
3	ErbB Receptors (EGF Receptor)IBA 02/2013 - 03/2004
3	Phosphotransferases (Kinase)IBA 05/2006 - 09/2003
2	B7-H1 AntigenIBA 01/2021 - 01/2018
2	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2018
2	purineIBA 07/2020 - 09/2015
2	Cetuximab (Erbitux)FDA Link 02/2019 - 02/2013
2	ezrinIBA 01/2019 - 08/2006
2	Long Noncoding RNAIBA 01/2018 - 01/2017
2	Dasatinib (BMS 354825)FDA Link 01/2018 - 03/2016
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2018 - 02/2013
2	Heme (Haem)IBA 10/2017 - 10/2017
2	BiguanidesIBA 10/2017 - 10/2017
2	CytochromesIBA 10/2017 - 10/2017
2	ParaffinIBA 12/2016 - 01/2012
2	OsteopontinIBA 09/2015 - 02/2003
2	Fluorouracil (Carac)FDA LinkGeneric 08/2015 - 04/2010
2	Cisplatin (Platino)FDA LinkGeneric 08/2015 - 04/2010
2	Small Interfering RNA (siRNA)IBA 06/2015 - 03/2007
2	ChromatinIBA 01/2015 - 09/2013
2	Phenobarbital (Luminal)FDA Link 11/2014 - 03/2013
2	ChemokinesIBA 06/2014 - 12/2002
2	Gemcitabine FDA Link 05/2014 - 01/2012
2	Checkpoint Kinase 1IBA 03/2014 - 12/2013
2	MyogeninIBA 11/2013 - 09/2013
2	DesminIBA 09/2013 - 06/2010
2	VimentinIBA 01/2011 - 03/2009
2	NF-kappa B (NF-kB)IBA 04/2010 - 08/2005
2	Selenium-Binding ProteinsIBA 04/2010 - 03/2004
2	PPAR gammaIBA 11/2009 - 04/2006
2	Lamin Type A (Lamin A)IBA 03/2009 - 06/2007
2	Doxorubicin (Adriamycin)FDA LinkGeneric 06/2007 - 03/2007
2	UbiquitinIBA 04/2007 - 12/2006
2	CyclinsIBA 12/2006 - 08/2005
2	Amino Acids FDA Link 04/2006 - 01/2004
2	Complementary DNA (cDNA)IBA 08/2005 - 01/2004
1	LectinsIBA 01/2023
1	Polysaccharides (Glycans)IBA 01/2023
1	Complement System Proteins (Complement)IBA 12/2022
1	PhycoerythrinIBA 01/2021
1	(2,4- dihydroxy- 5- isopropylphenyl)- (5- (4- methylpiperazin- 1- ylmethyl)- 1,3- dihydroisoindol- 2- yl)methanoneIBA 10/2020
1	CrizotinibIBA 02/2019

Therapy/Procedure

20	Therapeutics 01/2023 - 03/2002
9	Drug Therapy (Chemotherapy) 01/2019 - 03/2007
6	Radiotherapy 10/2020 - 08/2006
4	Neoadjuvant Therapy 09/2015 - 07/2003